Health Bulletin 12/January/2022
Overview
Here are Top Health stories of the day
India reports 1,94,720 fresh Covid-19 cases, active count crosses 9.5-lakh
Over 3000 Doctors In Haryana Go On Strike Over Pending Unmet Demands
Around 3000 government doctors began a state-wide protest in Haryana for their pending demands. The doctors under the Haryana Civil Medical Services Association are participating in the protest which has subsequently resulted in the shutting down the out-patient departments (OPDs) services at all government hospitals.
According to state president Dr Jasbir Singh Parmar, all medical services, including Covid and emergency duties would be shut down on January 14.
For more information check out the full story on the link below:
Over 3000 doctors in Haryana go on strike over pending unmet demands
AYUSH Doctors Performing Surgeries, Validity Of NEET For AYUSH Courses: HC To Hear Matter Together In March
Responding to the plea challenging the provision of common National Eligibility-cum-Entrance Test (NEET) for admission to AYUSH courses, the Delhi High Court bench comprising of Chief Justice DN Patel has pointed out the "double standard" of the AYUSH aspirants when on the one hand, they seek similar rights to operate like allopathic practitioners, and on the other, they are denying to appear in NEET.
"On a lighter side, you on one hand are saying you are competitive. But when asked to appear in NEET, you are saying we are not," the bench, also comprising Justice Jyoti Singh, told the counsel for the petitioner.
For more information check out the full story on the link below:
MCC NEET PG Counselling Scheme Modified, Check Out 5 Major Changes
With the release of NEET PG Counselling 2021, the Medical Counselling Committee (MCC) has notified about the 5 major changes in the counselling scheme for this academic year's PG medical admission process.
For more information check out the full story on the link below:
MCC NEET PG Counselling Scheme Modified, Check out 5 major changes
Covaxin Booster Dose Safe, Says Bharat Biotech
Covaxin manufacturer Bharat Biotech on Saturday said that the booster dose trials have shown "promising results" of long-term safety with "no serious adverse events"
The Hyderabad-based company announced the results on the safety and immunogenicity of COVAXIN (BBV152),a whole-virion inactivated COVID-19 vaccine as a booster dose.
"Covaxin trial demonstrated long-term safety with no serious adverse events. 90 per cent of recipients had a detectable neutralizing antibody response against the wild-type strain (six months after the second dose)." Bharat Biotech said in an official statement.
For more information check out the full story on the link below:
Speakers
